TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest update is out from HBM Holdings Ltd. ( (HK:2142) ).
HBM Holdings Ltd. announced that its investee company, Shanghai NK Cell Technology Co., LTD, has successfully completed an A+++ round of financing, raising nearly RMB100 million. This funding will be used to advance clinical trials and support the development of NK Cell-Tech’s product pipeline, reflecting strong investor confidence in its innovative immunotherapy platform.
More about HBM Holdings Ltd.
HBM Holdings Ltd. is a company incorporated in the Cayman Islands, focusing on biotechnology through its subsidiary Harbour BioMed (Shanghai) Technology Development Co., Ltd. The company invests in innovative therapies, particularly in the field of NK cell therapy, and holds a 10.90% equity interest in Shanghai NK Cell Technology Co., LTD.
Average Trading Volume: 9,600,108
Technical Sentiment Signal: Buy
Current Market Cap: HK$6.82B
See more insights into 2142 stock on TipRanks’ Stock Analysis page.